Cardiovascular Disease Risk Assessment   
Data Standard

HISO 10071:2019

Published May 2019

**Contributors**

Assoc Prof Susan Wells, University of Auckland

Thanks and acknowledgements to the contributors to the Ministry of Health’s 2018 *Cardiovascular Disease Risk Assessment and Management for Primary Care* publication, which this data standard supports: Assoc Prof Gerry Devlin, Dr Paul Drury, Dr Fraser Hamilton, Dr Ben Hudson, Katie Inker, Prof Rod Jackson, Prof Jim Mann, Dr Helen Rodenburg, Prof Tim Stokes, Dr Jim Vause, Assoc Prof Susan Wells, Prof Michael Williams and Vanessa Young.

Vascular Informatics using Epidemiology and the Web (VIEW) research to develop the equations that underpin the updated approach to cardiovascular risk assessment was funded by grants from the Health Research Council of New Zealand (HRC), The Healthier Lives National Science Challenge, and the Heart Foundation of New Zealand.

Acknowledgements to the HRC-VIEW Research Team, School of Population Health, University of Auckland for the algorithms, test cases and worked examples.

Citation: Ministry of Health. 2019. *HISO 10071:2019 Cardiovascular Disease Risk Assessment Data Standard*. Wellington: Ministry of Health.

Published in May 2019 by the Ministry of Health  
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-98-856877-5 (online)  
HP 7109

Health Information Standards Organisation (HISO) standards are published by the Ministry of Health for the New Zealand health and disability sector.



This document is available at health.govt.nz

|  |  |
| --- | --- |
| **CCBY** | This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made. |

Contents

[1 Introduction 1](#_Toc46146730)

[1.1 Background 1](#_Toc46146731)

[1.2 Purpose and scope of the data standard 3](#_Toc46146732)

[1.3 Revision history 4](#_Toc46146733)

[2 Data set specification 5](#_Toc46146734)

[2.1 Personal demographics 6](#_Toc46146735)

[2.2 Prior CVD and other exclusion criteria 9](#_Toc46146736)

[2.3 Clinical history 11](#_Toc46146737)

[2.4 Self-reported history 12](#_Toc46146738)

[2.5 Measured risk factors 13](#_Toc46146739)

[2.6 Medications 19](#_Toc46146740)

[3 Primary prevention equations 25](#_Toc46146743)

[3.1 PREDICT CVD v.2019 primary prevention equation for women (30–74 years) 27](#_Toc46146746)

[3.2 PREDICT CVD v.2019 primary prevention equation for men (30–74 years) 28](#_Toc46146748)

[3.3 PREDICT CVD v.2019 primary prevention equation for women with diabetes (30–74 years) 29](#_Toc46146750)

[3.4 PREDICT CVD v.2019 primary prevention equation for men with diabetes (30–74 years) 30](#_Toc46146753)

[4 Test cases and worked examples 32](#_Toc46146754)

[4.1 Patient A 32](#_Toc46146755)

[4.2 Patient B 33](#_Toc46146756)

[4.3 Patient C 34](#_Toc46146757)

[4.4 Patient D 35](#_Toc46146758)

[5 Requirements for software tools 37](#_Toc46146759)

[6 References 38](#_Toc46146760)

# Introduction

This data standard supports the implementation of CVD risk calculation using the agreed primary prevention equations.

## Background

In 2003, the Health Research Council of New Zealand (HRC) funded the PREDICT cohort study. The study’s purpose was to develop new cardiovascular disease (CVD) risk prediction models for the New Zealand population, while simultaneously supporting the implementation of CVD and diabetes guidelines through computerised decision support (Wells et al 2015).

As of December 2017, general practitioners (GPs) and nurses had conducted heart and diabetes checks for over 500,000 patients using the PREDICT web-based platform. With national ethics approval and permission from primary health care providers, unidentifiable data from these checks were sent to the University of Auckland HRC-VIEW research team. Through matching each individual’s encrypted National Health Index (NHI) number to national hospitalisation and mortality data sets, the researchers have developed the first of a series of new CVD risk assessment equations tailored to New Zealand populations.

These equations are described in the 2018 Ministry of Health publication [*Cardiovascular Disease Risk Assessment and Management for Primary Care*](https://www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care) (Ministry of Health 2018). ). The equations were updated further in 2018 and released for sector implementation in 2019.

The four CVD risk primary prevention equations are:

* General population

1. PREDICT CVD v.2019 primary prevention equation for women (30–74 years)
2. PREDICT CVD v.2019 primary prevention equation for men (30–74 years)

* Diabetes-specific

1. PREDICT CVD v.2019 primary prevention equation for women with diabetes (30–74 years)
2. PREDICT CVD v.2019 primary prevention equation for men with diabetes (30–74 years).

The PREDICT cohort study is an open cohort and will continue to grow. The primary prevention equations will be subject to regular review and will be updated as required. For example, the primary prevention equation for the general population (men and women) has been updated to include body mass index (BMI) in this standard and, as such, differs from the published equation (Pylypchuk et al 2018). In addition, development of new CVD risk equations is underway specifically for Māori, Pacific and South Asian populations, people aged over 75 years, those with serious mental illness and those who have had a previous CVD event. Accordingly, this data standard will be reviewed and updated as these developments occur.

### CVD risk assessment

The goal of a CVD risk assessment that also includes screening for diabetes is to reduce CVD risk for individuals and provide appropriate advice about reducing the risk of developing diabetes. A CVD risk assessment informs people about their risk of future fatal and non-fatal cardiovascular events and strategies to improve their heart health. It also helps identify people with diabetes, to enable them to receive care and learn about helpful lifestyle changes. The overarching principle remains that the intensity of recommended interventions should be proportional to the estimated combined CVD risk.

### CVD risk calculation

The risk of an individual having a CVD event in the next five years can be estimated by a statistical model that combines multiple CVD risk factors into one algorithm or equation. When an individual’s risk profile is put into the equation, a five-year risk score can be calculated. This calculation has been found to accurately predict future population CVD events in the next five years. As the CVD event rate in New Zealand populations changes over time, it is important for primary health care providers to have the most up-to-date algorithms.

### CVD events predicted

The CVD risk calculation predicts the five-year risk of the following fatal and non-fatal CVD events: myocardial infarction, angina, coronary insufficiency, sudden and non-sudden coronary death, stroke (ischaemic or haemorrhagic), transient ischaemic attack, peripheral vascular disease (including claudication) and heart failure.

### Exclusions from CVD risk assessment using the primary prevention equations

All past, current and future CVD risk prediction equations are not intended to be used if the patient is pregnant.

Other specific exclusion criteria are:

* being less than 18 years of age
* people with known CVD (angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, ischaemic stroke, transient ischaemic attack or peripheral vascular disease
* heart failure diagnosed clinically
* having familial hypercholesterolaemia
* renal failure, defined as having an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2
* a history of renal transplantation or of being on dialysis
* diabetes and overt nephropathy (albumin to creatinine ratio greater than or equal to 30 mg/mmol)
* diabetes with other renal disease (eGFR less than 45 mL/min/1.73 m2).

If the patient’s profile does not meet any of the exclusion criteria listed above or is not otherwise clinically determined as being at very high risk, then a CVD risk calculation can be conducted using the primary prevention equations.

### Equations that can be used for patients with diabetes

Either general population or diabetes-specific equations can be used for people with diabetes. However, as the diabetes equation has further diabetes-specific variables included (such as ACR, diabetes medications), it is more accurate and tailored to a patient’s diabetes risk profile.

If the full dataset for patients with diabetes is not available, then it is reasonable to calculate the patient’s risk score using the general population primary prevention equation.

### Patients with type 1 diabetes

The PREDICT diabetes-specific primary prevention score has been developed in a cohort of people with type 2 diabetes (or type unknown). The equations can be used for type 1 diabetes, although this is likely to be an underestimate. Future equations for patients with type 1 diabetes will be developed as the PREDICT cohort accrues larger numbers of people with type 1 diabetes and new scores, as they are developed.

## Purpose and scope of the data standard

The purpose of the data standard is to support the implementation of CVD risk calculation in patient management systems and clinical decision support tools by providing specifics of the primary prevention equations and their use.

The data standard includes:

* a data set specification for the personal health information needed for CVD risk calculation
* the set of variables and coefficients for each primary prevention equation
* requirements for software tools implementing the primary prevention equations and supporting CVD risk assessment.

## Revision history

|  |  |
| --- | --- |
| **28 May 2019** | First published |
| **21 July 2020** | Minor update to:   * Align description of exclusion criteria with the published clinical guidelines * Standardise equation names * Add test cases and worked examples * Add SNOMED CT concepts for the equations |

# Data set specification

This section provides a data set specification for the input variables required for CVD risk calculation using the primary prevention equations.

The data set covers:

* personal demographics
* prior CVD and other exclusion criteria
* clinical history
* self-reported history
* measured risk factors
* medication.

#### Data element template

Data element specifications in this standard conform to the requirements of *ISO/IEC 11179* *Information Technology – Metadata Registries (MDR)*.[[1]](#footnote-2)

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | A statement that expresses the essential nature of the data element and its differentiation from other elements in the data set. | | |
| **Source standards** | Established standards or guidelines pertaining to the data element. | | |
| **Data type** | Alphabetic (A)  Date  Date/time  Numeric (N)  Alphanumeric (X)  Boolean  SNOMED CT identifier | **Representational class** | Code  Free text  Value  Identifier  Indicator |
| **Field size** | Maximum number of characters | **Representational layout** | For example:   * X(50) for a 50-character alphanumeric string * NNN for a 3-digit number * NNAAAA for a formatted alphanumeric identifier |
| **Data domain** | The valid values or codes that are acceptable for the data element.  Each coded data element has a specified code set. | | |
| **Obligation** | Indicates if the data element is mandatory or optional, or whether its appearance is conditional in the context. | | |
| **Guide for use** | Additional guidance to inform the use of the data element. | | |
| **Verification rules** | Quality control mechanisms that preclude invalid values. | | |

#### Clinical terminology standard

Most coded data elements use by default the SNOMED CT terminology for clinical information. The concepts making up each data domain are denoted by preferred term and linked to entries in the [SNOMED CT browser](http://browser.snomedtools.org/). The SNOMED CT concept identifier can be viewed by hovering over the link.

Some data elements are restricted to a definite set of SNOMED CT concepts, while others are more open-ended and allow the user to select from a wider set of concepts, usually within a certain hierarchy or sub-hierarchy – eg, the set of all disease concepts. See the [SNOMED CT Search and Data Entry Guide](https://confluence.ihtsdotools.org/display/DOCSEARCH/SNOMED+CT+Search+and+Data+Entry+Guide) for a guide to building a user-friendly search across the terminology.

The [SNOMED NZ Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps), incorporating the SNOMED CT International Edition and released in April and October every year, is the standard distribution. SNOMED CT is free to use in New Zealand and easy to implement. To ensure compatibility between SNOMED concepts and Read codes, a cross mapping is published in the SNOMED NZ Edition.

The [New Zealand Medicines Terminology (NZMT)](https://view.nzmt.org.nz/home) is the SNOMED CT-based terminology used to standardise the naming of every medicinal product available in New Zealand.

## Personal demographics

### Age

Age is an important non-modifiable predictor of a CVD event. The primary prevention risk prediction equations were developed from a cohort of people aged 30 to 74 years who were eligible for CVD risk prediction according to the 2003 CVD risk assessment and management guidelines (and subsequent updates) (New Zealand Guidelines Group 2003). A risk calculation outside this age range will be an approximation but potentially useful. Clinical judgement is recommended. For risk calculation purposes, the person’s actual age should be input.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Age in whole years at date of risk calculation | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | 18–110 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Either:   1. calculated in the input template by subtracting date of birth from the date of risk calculation and dividing by 365.25 2. populated from the patient’s health record 3. entered by self-report.   The CVD risk equations were developed for ages 30 to 74 years. Use outside this age range will be an approximation but still potentially useful | | |
| **Verification rules** | Must be within valid age range | | |

### Biological sex

A person’s biological sex is an important predictor of a future CVD event, with men being at higher risk and demonstrating differing weightings of other risk factors within a multivariate risk prediction equation compared with women. Therefore, biological sex, rather than sexual identity, is used in CVD risk prediction equations. However, in discussion between the clinician and the patient, a person treated on long-term oestrogens could be considered biologically female; a person on long-term testosterone could be considered biologically male.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Biological sex for the purpose of risk calculation | | |
| **Source standards** |  | | |
| **Data type** | SNOMED CT identifier | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Data domain** | [Male](https://browser.ihtsdotools.org/?perspective=full&conceptId1=248153007)  [Female](https://browser.ihtsdotools.org/?perspective=full&conceptId1=248152002) | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Male or female biological risk is determined in discussion between the clinician and the patient  CVD risk equations apply according to sex-specific grouping | | |
| **Verification rules** |  | | |

### Ethnicity

Ethnicity in this context is for the purpose of CVD risk calculation.

[HISO 10001:2017 Ethnicity Data Protocols](https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocols) supports recording up to six ethnicities at level 4. It is assumed that self-reported ethnicity is collected appropriately in primary health care services, using the standard ethnicity question and coded as per Statistics New Zealand (Stats NZ) [Ethnicity New Zealand Standard Classification 2005 v2.0.0](http://aria.stats.govt.nz/aria/?_ga=2.75320529.294646729.1590721436-1806882675.1588740120#ClassificationView:uri=http://stats.govt.nz/cms/ClassificationVersion/l36xYpbxsRh7IW1p).

In the development of the CVD risk prediction equations, ethnicities were prioritised and aggregated into five ethnic categories, ordered as: (1) Māori, (2) Pacific, (3) Indian/Other South Asian, (4) Chinese/Other Asian, (5) European/Other.

For risk calculation purposes, it is recommended that putting ethnicity data into the template follow the same rule. That is, if a person self-identifies as being Chinese, European and Māori, then they should be inputted as Māori to the risk calculator. The only exception to this rule is if people self-identify as being both Fijian and Indian. From an epidemiological perspective when developing the equations, these individuals most closely resemble the risk profile of Indian and should be input as such.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Prioritised ethnic category | | |
| **Source standards** | HISO 10001:2017 Ethnicity Data Protocols  Stats NZ Ethnicity New Zealand Standard Classification 2005 | | |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 5 | **Representational layout** | NNNNN |
| **Data domain** | Māori – 21111, level 2 code 21  Pacific – Level 2 codes 35, 36, 34, 33, 32, 31, 37, 30  Indian/Other South Asian – Level 2 code 43 (including Fijian Indian 43112), Sri Lankan (441, 44100), Sinhalese (44111), Sri Lankan Tamil (44112), Sri Lankan nec (44199), Afghani (44411), Bangladeshi (44412), Nepalese (44413), Pakistani (44414), Tibetan (44415)  Chinese/Other Asian – Level 2 code 41, 42, 44 (if not included in the Indian/Other South Asian category), 40  European and Other – Level 2 codes 52, 53, 51, 61, 12, 10, 11, 91, 95, 97, 99 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Ethnicity should be recorded at level 4 in the patient’s health record  Apply the prioritisation rules to determine the ethnic category and use the most specific code to record it  Level 2 and 3 codes encompass the level 4 codes they prefix | | |
| **Verification rules** |  | | |

### Deprivation index

The New Zealand Deprivation Index (NZDep) score is a measure for assessing socioeconomic status and is a significant predictor of CVD risk, independent of other risk factors.

NZDep is a measure assigned to a patient’s area of residence. The score is based on nine variables from the Census, reflecting eight dimensions of relative deprivation of census tracts (Salmond et al 2007). NZDep is updated with each Census (eg, 2006, 2013, 2018), so the index closest to the CVD risk calculation should be used if available. For CVD risk calculation, input NZDep according to quintile of deprivation (from 1 least deprived to 5 most deprived).

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | NZDep score expressed as quintile of deprivation | | |
| **Source standards** | [NZDep](https://www.otago.ac.nz/wellington/departments/publichealth/research/hirp/otago020194.html) | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 1–5 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | NZDep score is derived each census (eg, 2006, 2013, 2018). Use the NZDep closest to the date of CVD risk calculation  If NZDep score is unknown, use the NZiDep index of socioeconomic deprivation for individuals (Salmond et al 2006). This eight-question survey can provide quintile of deprivation for putting into the risk calculator | | |
| **Verification rules** |  | | |

## Prior CVD and other exclusion criteria

### Prior CVD

Prior CVD is defined as having had one or more of the following conditions or procedures. These are all related to atherosclerotic arterial disease of the heart, brain and peripheral vessels:

* angina
* myocardial infarction
* percutaneous coronary intervention
* coronary artery bypass grafting
* ischaemic stroke
* transient ischaemic attack
* peripheral vascular disease (clinical diagnosis or procedure).

If a prior CVD condition or procedure is present, then individuals are excluded from CVD risk assessment using the primary prevention equations. However, these conditions and procedures are included in the table below as they need to be explicitly reported at the time of CVD risk assessment and will be variables within future secondary prevention equations.

|  |  |
| --- | --- |
| **Condition or procedure** | **Definition** |
| [Angina](https://browser.ihtsdotools.org/?perspective=full&conceptId1=22298006) | History of stable or unstable angina |
| [Myocardial infarction](https://browser.ihtsdotools.org/?perspective=full&conceptId1=22298006) | Previous heart attack or acute coronary syndrome, including both non-ST elevation myocardial infarction (non-STEMI) and ST elevation myocardial infarction (STEMI) |
| [Percutaneous coronary intervention](https://browser.ihtsdotools.org/?perspective=full&conceptId1=415070008) | Previous percutaneous coronary intervention, including coronary angioplasty and stenting |
| [Coronary artery bypass grafting](https://browser.ihtsdotools.org/?perspective=full&conceptId1=232717009) | Previous coronary artery bypass grafting procedure |
| [Ischaemic stroke](https://browser.ihtsdotools.org/?perspective=full&conceptId1=422504002) | Previous ischaemic stroke with neurological signs and symptoms lasting more than 24 hours |
| [Transient ischaemic attack](https://browser.ihtsdotools.org/?perspective=full&conceptId1=266257000) (TIA) | Previous history of TIA – signs and symptoms typical of a stroke but with full recovery in less than 24 hours |
| [Peripheral vascular disease](https://browser.ihtsdotools.org/?perspective=full&conceptId1=400047006):   * [Peripheral ischaemia](https://browser.ihtsdotools.org/?perspective=full&conceptId1=233958001) * [History of peripheral vascular disease procedure](https://browser.ihtsdotools.org/?perspective=full&conceptId1=301433005) * [Aneurysm of artery of trunk](https://browser.ihtsdotools.org/?perspective=full&conceptId1=301433005) * [Aneurysm of peripheral artery](https://browser.ihtsdotools.org/?perspective=full&conceptId1=29721000119101) * [Carotid artery stenosis](https://browser.ihtsdotools.org/?perspective=full&conceptId1=64586002) * [Intermittent claudication](https://browser.ihtsdotools.org/?perspective=full&conceptId1=63491006) * [Pain at rest due to peripheral vascular disease](https://browser.ihtsdotools.org/?perspective=full&conceptId1=428171009) | Atherosclerotic peripheral vascular disease of any peripheral arteries (eg, to legs and feet), including renal, carotid and vertebral arteries. Diagnosis could be based on:   * clinical signs and symptoms, such as intermittent claudication * diminished foot pulses or carotid bruits * radiological evidence or atherosclerotic arterial disease or prior surgical procedures * abdominal aortic aneurysm * carotid stenosis or asymptomatic carotid disease (including plaque identified on carotid ultrasound) |

A reference set listing the above conditions and procedures will be published in the SNOMED NZ Edition.

### Other exclusion criteria

There are four more conditions or findings that meet exclusion criteria for CVD risk calculation via primary prevention equations (both general population and diabetes-specific equations). These disorders are associated with CVD event risks similar to those with prior CVD and need to be explicitly reported at the time of CVD risk assessment.

|  |  |
| --- | --- |
| **Condition or findings** | **Definition** |
| [Heart failure](https://browser.ihtsdotools.org/?perspective=full&conceptId1=84114007) | Clinical diagnosis of heart failure |
| [Familial hypercholesterolaemia](https://browser.ihtsdotools.org/?perspective=full&conceptId1=398036000) | Raised levels of total cholesterol and low-density lipoprotein (LDL) cholesterol consistent with autosomal dominant inheritance. This requires a specialist diagnosis and is associated with family tracing |
| [Renal failure](https://browser.ihtsdotools.org/?perspective=full&conceptId1=42399005&edition=en-edition&release=v20180731&server=https://browser.ihtsdotools.org/api/v1/snomed&langRefset=900000000000509007)   * [Chronic kidney disease stage 4](https://browser.ihtsdotools.org/?perspective=full&conceptId1=431857002) * [Chronic kidney disease stage 5](https://browser.ihtsdotools.org/?perspective=full&conceptId1=433146000) * [Chronic kidney disease stage 5 with transplant](https://browser.ihtsdotools.org/?perspective=full&conceptId1=714153000) * [Chronic kidney disease stage 5 on dialysis](https://browser.ihtsdotools.org/?perspective=full&conceptId1=714152005) | A history of renal transplantation, chronic renal dialysis or having an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 |
| [Overt diabetic nephropathy](https://browser.ihtsdotools.org/?perspective=full&conceptId1=445170001) | Having diabetes and an urinary albumin to creatinine ratio (ACR)≥30 mg/mmol |

A SNOMED reference set listing the above conditions will be published in the SNOMED NZ Edition.

## Clinical history

A history of atrial fibrillation, diabetes and duration of diabetes, and family history of premature ischaemic CVD are input variables to the CVD primary prevention equations.

### Atrial fibrillation

Atrial fibrillation (AF) is a common abnormal heart rhythm that increases the risk of stroke. AF is clinically diagnosed after electrocardiogram (ECG) confirmation. It is characterised by an irregularly irregular heart beat and may occur on and off (paroxysmal atrial fibrillation), or it may continue indefinitely (persistent or permanent atrial fibrillation). AF may be a new finding or a long-term disorder.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | ECG-confirmed atrial fibrillation | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes, [ECG confirmed atrial fibrillation](https://browser.ihtsdotools.org/?perspective=full&conceptId1=164889003) | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Input value determined from SNOMED-coded clinical diagnosis in the patient record | | |
| **Verification rules** |  | | |

### Diabetes

Diabetes is a chronic disease that occurs when the pancreas is not able to produce enough insulin or when the body cannot effectively use the insulin it makes. This leads to hyperglycaemia (raised glucose level in the blood), which over the long term can damage organs and tissues. It is an independent predictor of cardiovascular events.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Diagnosed with type 1 diabetes, type 2 diabetes or type unknown | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No diabetes  1 = [Diabetes mellitus type 1](https://browser.ihtsdotools.org/?perspective=full&conceptId1=46635009)  1 = [Diabetes mellitus type 2](https://browser.ihtsdotools.org/?perspective=full&conceptId1=44054006)  1 = [Diabetes type unknown](https://browser.ihtsdotools.org/?perspective=full&conceptId1=73211009) | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Input value determined from SNOMED-coded clinical diagnosis in the patient record | | |
| **Verification rules** |  | | |

### Duration of diabetes

The longer the time a person has diabetes, the greater the risk of vascular disease. Duration of diabetes is included in the diabetes-specific primary prevention models.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Length of time in completed years a patient has had a diagnosis of diabetes | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | 0–100 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Self-reported or clinical diagnosis  Calculate by subtracting the year of electronic submission from the year of diagnosis of diabetes  This represents completed years since diagnosis and could also be estimated by a clinician and patient if the year of diagnosis is unknown | | |
| **Verification rules** |  | | |

## Self-reported history

### Family history of premature ischaemic CVD

A family history of premature ischaemic CVD in a parent or sibling is associated with an increased risk of a CVD event and included as a predictor in the primary prevention equations.

Note change in age definition from previous CVD risk assessment and management guidelines.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Having a first-degree relative (parent or sibling) who was hospitalised or died from a heart attack or stroke before the age of 50 years | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = [No family history of cardiovascular disease in first degree relative less than 50 years of age](https://browser.ihtsdotools.org/?perspective=full&conceptId1=371000210103&edition=MAIN/SNOMEDCT-NZ/2020-04-01&release=&languages=en)  1 = [Family history of cardiovascular disease in first degree relative less than 50 years of age](https://browser.ihtsdotools.org/?perspective=full&conceptId1=361000210109&edition=MAIN/SNOMEDCT-NZ/2020-04-01&release=&languages=en) | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Self-reported | | |
| **Verification rules** |  | | |

### Smoking status

The variables below represent smoking status and refer primarily to cigarette smoking. The previous equation used in the New Zealand CVD guidelines was derived from the Framingham Heart study and included people who had recently quit smoking within the previous 12 months as having an equivalent risk to those currently smoking. The new primary prevention equations have demonstrated that all ex-smokers (less than or greater than 12 months) have an equivalent risk after adjusting for other risk factors.

#### Currently smoking

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Currently smoking | | |
| **Source standards** | HISO 10073:2020 Smoking Cessation Data Standard to be published | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 1 = [Currently smoking](https://browser.ihtsdotools.org/?perspective=full&conceptId1=77176002)  0 otherwise | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Self-reported and/or determined from smoking status in the patient record | | |
| **Verification rules** |  | | |

#### Ex-smoking

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Ex-smoking | | |
| **Source standards** | HISO 10073:2020 Smoking Cessation Data Standard to be published | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 1 = [Ex-smoking](https://browser.ihtsdotools.org/?perspective=full&conceptId1=8517006)  1 = [Ex-smoking for less than 1 year](https://browser.ihtsdotools.org/?perspective=full&conceptId1=735128000)  1 = [Ex-smoking for more than 1 year](https://browser.ihtsdotools.org/?perspective=full&conceptId1=48031000119106)  0 otherwise | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Self-reported and/or determined from SNOMED-coded smoking status in the patient record | | |
| **Verification rules** |  | | |

## Measured risk factors

### Blood pressure

Blood pressure (BP) is typically recorded as having systolic and diastolic measurements in mmHg. The ideal BP for most individuals is likely to be below 120 mmHg systolic and 75 mmHg diastolic. Above this level, the risk of a CVD event increases continuously with increasing BP.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Systolic BP – the average of two seated measurements in mmHg taken on two separate occasions (at least 10 minutes apart) | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | 40 ≤ value ≤ 310 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical measurement from a sphygmomanometer  Although both systolic and diastolic BP are collected, only systolic BP is presently used in the CVD risk equations  BP measurements should be recorded with a date in the patient’s health record | | |
| **Verification rules** | Systolic BP must be greater than diastolic BP | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Diastolic BP – the average of two seated measurements in mmHg taken on two separate occasions (at least 10 minutes apart) | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | 20 ≤ diastolic BP ≤ 200 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical measurement from a sphygmomanometer  Although both systolic and diastolic BP are collected, only systolic BP is presently used in the CVD risk equations  BP measurements should be recorded with a date in the patient’s health record | | |
| **Verification rules** | Systolic BP must be greater than diastolic BP | | |

### Weight

Weight in kilograms is used in conjunction with height in metres to calculate a body mass index (BMI).

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Body weight in kilograms | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | 30 ≤ value ≤ 350 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Measured in a clinical setting  For calculating BMI | | |
| **Verification rules** |  | | |

### Height

Weight in kilograms is used in conjunction with height in metres to calculate a body mass index (BMI).

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Body height in metres | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | N.NN |
| **Data domain** | 1.00 ≤ value ≤ 2.30 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Measured in a clinical setting  For calculating BMI | | |
| **Verification rules** |  | | |

### Body mass index

An individual’s body mass index (BMI) is calculated by weight in kilograms divided by height in metres squared (kg/m2). BMI is associated with CVD event risk independently of the presence of diabetes, blood pressure and lipid levels. BMI has been included in general population and diabetes primary prevention equations either as a categorical variable or continuous variable.

The continuous variable is defined as follows.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | A measure in kg/m2 derived from weight in kilograms and height in metres | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NN.N |
| **Data domain** | BMI is a continuous variable for diabetes-specific primary prevention equations | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Calculated in kg/m2 from height and weight measurements  BMI is used as a continuous measure in the diabetes-specific primary prevention equations | | |
| **Verification rules** |  | | |

The categorical variable is derived from the continuous variable and defined as follows.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Categorical variable based on a measure in kg/m2 derived from weight in kilograms and height in metres | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | For general population primary prevention equations, BMI is a categorical variable:  0 = 18.5 ≤ value < 25.0  1 = value <18.5  2 = 25.0 ≤ value < 30.0  3 = 30.0 ≤ value < 35.0  4 = 35.0 ≤ value < 40.0  5 = 40.0 ≤ value  6 = unknown | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Derived from calculation in kg/m2 from height and weight measurements  BMI is used as a categorical variable in the general population primary prevention equation and allows for BMI status to be missing or unknown | | |
| **Verification rules** |  | | |

### Total cholesterol

A single non-fasting total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) test is required to calculate a TC:HDL-C ratio in the primary prevention equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | A single non-fasting total cholesterol measurement in mmol/L | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 4 | **Representational layout** | NNN.N |
| **Data domain** | 1.0 ≤ value ≤ 103.6 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result with NZPOCS code  For calculation of TC:HDL-C | | |
| **Verification rules** |  | | |

### High-density lipoprotein cholesterol

A single non-fasting total cholesterol (TC) and high-density lipoprotein cholesterol (HDL) is required to calculate a TC:HDL-C ratio in the primary prevention equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Use a single non-fasting HDL-C measurement in mmol/L | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NN.N |
| **Data domain** | 0.13 ≤ value ≤ 51.8 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result with NZPOCS code  For calculation of TC:HDL-C | | |
| **Verification rules** |  | | |

### Non fasting total cholesterol to high-density lipoprotein cholesterol ratio

For CVD risk prediction, the non-fasting total cholesterol to high-density lipoprotein cholesterol ratio (TC:HDL-C) is a better predictor of CVD event risk than any of the other lipid fractions.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Single non-fasting total cholesterol to high-density lipoprotein cholesterol (TC:HDL-C) ratio | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 4 | **Representational layout** | NN.NN |
| **Data domain** | 1.08 ≤ value ≤ 30.1 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Calculate from laboratory test results for total cholesterol and high-density lipoprotein cholesterol  Cannot be calculated if an accurate HDL-C measurement is not available (eg, because of elevated triglyceride level) | | |
| **Verification rules** |  | | |

### Serum creatinine

Serum creatinine is a laboratory test for kidney function. It is used in the CKD-Epi Study equation to derive an estimated glomerular filtration rate (eGFR).

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Laboratory test result for serum creatinine measured in umol/L | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 4 | **Representational layout** | NNNN |
| **Data domain** | 20 ≤ value < 5000 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result with NZPOCS code  Used to calculate the eGFR using the CKD-Epi Study equation | | |
| **Verification rules** |  | | |

### Estimated glomerular filtration rate

The estimated glomerular filtration rate (eGFR) is a measure of kidney function with normal levels being above 90 mL/min/1.73 m2. If the eGFR is consistently less than 30 mL/min/1.73 m2, then the individual has chronic kidney disease stage 4 or 5 (or chronic renal failure). At this level, they are estimated to have the CVD risk of someone with prior CVD and are excluded from having a risk score calculated using primary prevention equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | eGFR in units of mL/min/1.73 m2 derived using a validated equation | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | NNN |
| **Data domain** | Based on age and serum creatinine valid ranges | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result for serum creatinine identified by NZPOCS code  CKD-Epi Study equation denoted by the formula:     * Scr is serum creatinine in mg/dl (use 0.0113 as unit conversion from u/mol) * κ is 0.7 for females and 0.9 for males * α is -0.329 for females and -0.411 for males * min indicates the minimum of Scr/κ or 1 * max indicates the maximum of Scr/κ or 1   Note: Ethnicity coefficient for African American is not applied for New Zealand  If eGFR < 30 mL/min/1.73 m2, then the patient is excluded from CVD risk calculation using the primary prevention equations. | | |
| **Verification rules** |  | | |

### HbA1c

HbA1c is a measure of glycated haemoglobin and is used for screening for diabetes or monitoring glycaemic control for people with diabetes.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Non-fasting laboratory test measuring glycated haemoglobin in mmol/mol | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 4 | **Representational layout** | NNNN |
| **Data domain** | 20 < value < 5000 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result identified by NZPOCS code | | |
| **Verification rules** |  | | |

### Urinary albumin to creatinine ratio (for people with diabetes)

The 2018 CVD consensus statement recommends collecting a urinary albumin to creatinine ratio (ACR), also known as urinary microalbumin, at least annually for all people with diagnosed diabetes. This test helps identify kidney disease that can occur as a complication of diabetes. If a person has an ACR consistently above 30mg/mmol, they are diagnosed as having overt diabetic nephropathy or macroalbuminuria. At this level, they will have the CVD risk of someone with prior CVD and are excluded from having a risk score calculated using primary prevention equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Urinary ACR laboratory test measurement in mg/mmol | | |
| **Source standards** | NZPOCS | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 5 | **Representational layout** | NNNN.N |
| **Data domain** | 0.1 < value < 5650.0 | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Laboratory test result with NZPOCS code  Test result needed for diabetes primary prevention equations only  If ACR ≥ 30 then it is excluded for all primary prevention equations (general population and diabetes specific equations) | | |
| **Verification rules** |  | | |

## Medications

Medications in the patient’s health record should be represented using the New Zealand Medicines Terminology (NZMT).

A mapping between SNOMED CT and NZMT medicinal products is published in the SNOMED NZ Edition to enable interoperability and clinical decision support. The list of medicines and substances under each of the following headings will be published as a reference set in the SNOMED NZ Edition.

### Lipid-lowering medication

Being on any lipid-lowering medication, if prescribed in the six months before a CVD risk assessment, is included as a variable in the CVD risk equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | On lipid-lowering medication  The patient has been prescribed one or more medications that lower lipids (statins or other medications) in the previous six months | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

#### Lipid-lowering medications (as at publication date)

As new statins or other lipid-lowering medications are approved, they will be added to this list.

|  |  |
| --- | --- |
| **Sub-category** | **Product/substance** |
| Statin | pravastatin  simvastatin  atorvastatin  [fluvastatin](https://browser.ihtsdotools.org/?perspective=full&conceptId1=387585004&edition=en-edition&release=v20180731&server=https://browser.ihtsdotools.org/api/v1/snomed&langRefset=900000000000509007)  ezetimibe + simvastatin |
| Other lipid-lowering drugs | acipimox  bezafibrate  cholestyramine  clofibrate  colestipol hydrochloride  ezetimibe  ezetimibe + simvastatin  gemfibrozil  nicotinic acid |

### Blood pressure lowering medication

Being on a blood pressure lowering medication, if prescribed in the six months before a CVD risk assessment, is included as a variable in the CVD risk equations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | On blood pressure lowering medication  The patient has been prescribed one or more medications that lower blood pressure – eg, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blocker (ARB), beta blockers, calcium channel blockers, thiazides and other BP-lowering medications – in the previous six months | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

#### Blood pressure lowering medications (as at publication date)

As new blood pressure lowering medications are approved, they will be added to the list.

|  |  |
| --- | --- |
| **Sub-category** | **Product/substance** |
| ACE inhibitor | captopril, perindopril, lisinopril, benazepril, quinapril, cilazapril, enalapril maleate, trandolapril, quinapril + hydrochlorothiazide, captopril + hydrochlorothiazide, lisinopril + hydrochlorothiazide, enalapril maleate + hydrochlorothiazide, cilazapril + hydrochlorothiazide |
| Angiotensin II receptor blocker | losartan with hydrochlorothiazide, candesartan cilexetil, losartan potassium, losartan + hydrochlorothiazide, losartan potassium + hydrochlorothiazide, losartan |
| Beta-blocker | carvedilol, celiprolol, timolol (not eye drops), sotalol, propranolol, pindolol, oxprenolol, nadolol, metoprolol tartrate, metoprolol succinate, labetalol, atenolol, alprenolol, acebutolol, acebutolol + hydrochlorothiazide, pindolol + clopamide, atenolol + chlorthalidone, bisoprolol fumarate |
| Calcium channel blocker | amlodipine, diltiazem hydrochloride, felodipine, isradipine, nifedipine, verapamil hydrochloride, verapamil hydrochloride |
| Thiazide | acebutolol + hydrochlorothiazide, amiloride hydrochloride + hydrochlorothiazide, atenolol + chlorthalidone, bendroflumethiazide (bendrofluazide), captopril + hydrochlorothiazide, chlorothiazide, chlortalidone (Chlorthalidone), cilazapril + hydrochlorothiazide, cyclopenthiazide, enalapril maleate + hydrochlorothiazide, indapamide, lisinopril + hydrochlorothiazide, losartan, losartan potassium + hydrochlorothiazide, losartan + hydrochlorothiazide, losartan + hydrochlorothiazide, methyclothiazide, methyldopa + hydrochlorothiazide, quinapril + hydrochlorothiazide, triamterene + hydrochlorothiazide |
| Other blood pressure lowering drugs | amiloride hydrochloride, amiloride hydrochloride + furosemide, amiloride hydrochloride + hydrochlorothiazide, clonidine, clonidine hydrochloride, hydralazine hydrochloride, methyldopa, methyldopa + hydrochlorothiazide, pindolol + clopamide, triamterene + hydrochlorothiazide |

### Antithrombotic medication

Being on an antithrombotic medication, if prescribed in the six months before a CVD risk assessment, is included in the CVD risk equations.

The variable is split into the two sub-categories antiplatelet agents and anticoagulants. As further risk equations are likely to be developed for i) atrial fibrillation and ii) bleeding risk from antiplatelet agents, these sub-categories should be collected separately.

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | On antithrombotic medication  The patient has been prescribed either an antiplatelet or an anticoagulant in the previous six months | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications  Combination of antiplatelet or anticoagulant medication used in CVD risk prediction equations | | |
| **Verification rules** |  | | |

#### Antiplatelet agents

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | On antiplatelet medication  The patient has been prescribed one or more medications that are used as antiplatelet agents (eg, aspirin, clopidogrel) in the previous six months | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

#### Antiplatelet medications (as at publication date)

As new antiplatelet medications are approved, they will be added to this list.

|  |  |
| --- | --- |
| **Sub-category** | **Product/substance** |
| Aspirin | aspirin |
| Clopidogrel | clopidogrel |
| Ticagrelor | ticagrelor |
| Other antiplatelet | dipyridamole (1)  prasugrel  ticlopidine hydrochloride |

#### Anticoagulant agents

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | On anticoagulant medication  The patient has been prescribed one or more medications that are used as anticoagulant agents (eg, warfarin, dabigatran) in the previous six months | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = No  1 = Yes | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

#### Anticoagulant medications (as at publication date)

As new anticoagulant medications are approved they will be added to this list.

|  |  |
| --- | --- |
| **Sub-category** | **Product/substance** |
| Warfarin | warfarin sodium |
| Other anticoagulants | phenindione  dabigatran  rivaroxaban  apixaban |

### Diabetes medications

Being on any of the following types of medication used for glycaemic control for diabetes is an input to the diabetes-specific primary prevention equations.

#### Diabetes medications (as at publication date)

As new diabetes medications are approved, they will be added to this list.

|  |  |
| --- | --- |
| **Sub-category** | **Product/substance** |
| Insulin | insulin lispro  insulin neutral  insulin isophane  insulin zinc suspension  insulin aspart  insulin glargine  glucagon hydrochloride |
| Metformin | metformin hydrochloride |
| Other oral-hypoglycaemic agents | sulfonylurea  thiazolidinedione  rosiglitazone  pioglitazone  tolbutamide  tolazamide  glipizide  gliclazide  glibenclamide  [acarbose](https://browser.ihtsdotools.org/?perspective=full&conceptId1=386965004&edition=en-edition&release=v20180731&server=https://browser.ihtsdotools.org/api/v1/snomed&langRefset=900000000000509007)  sitagliptin  saxagliptin  vildagliptin  exenatide  dapagliflozin |

#### Insulin

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | The use of the insulin hormone to support glycaemic control in people with diabetes | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = None  1 = Insulin | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

#### Oral hypoglycaemic medications

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition** | Oral medications used to support glycaemic control in people with diabetes | | |
| **Source standards** |  | | |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 1 | **Representational layout** | N |
| **Data domain** | 0 = None  1 = Metformin or other hypoglycaemic medications | | |
| **Obligation** | Mandatory | | |
| **Guide for use** | Clinical criteria based on long-term medications | | |
| **Verification rules** |  | | |

# Primary prevention equations

The tables in this section provide the variables, coefficients and other calculation details for each of the four current primary prevention equations.

The equations are:

* [PREDICT CVD v.2019 primary prevention equation for women (30–74 years)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50681000210105&edition=MAIN/SNOMEDCT-NZ/2020-04-01)
* [PREDICT CVD v.2019 primary prevention equation for men (30–74 years)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50741000210105&edition=MAIN/SNOMEDCT-NZ/2020-04-01)
* [PREDICT CVD v.2019 primary prevention equation for women with diabetes (30–74 years)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50701000210107&edition=MAIN/SNOMEDCT-NZ/2020-04-01)
* [PREDICT CVD v.2019 primary prevention equation for men with diabetes (30–74 years)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50711000210109&edition=MAIN/SNOMEDCT-NZ/2020-04-01).

Earlier versions of the first two equations, implemented by Enigma Solutions, in 2018 have these names:

* [PREDICT CVD v.2018 primary prevention equation for women (30–74 years)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50721000210104&edition=MAIN/SNOMEDCT-NZ/2020-04-01)
* [PREDICT CVD v.2018 primary prevention equation for men (30–74 years](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50761000210106&edition=MAIN/SNOMEDCT-NZ/2020-04-01))

For clarity and with permission from Enigma Solutions, here are the [Enigma Your Heart Engine™ codes](https://www.yourheartengine.co.nz/versions/) for the two sets of equations.

|  |  |
| --- | --- |
| **Enigma code** | **Set of equations** |
| YHE-2018-BMI | PREDICT CVD v.2018 primary prevention equation for women (30–74 years)  PREDICT CVD v.2018 primary prevention equation for men (30–74 years) |
| YHE-2019-BMI-DM | PREDICT CVD v.2019 primary prevention equation for women (30–74 years)  PREDICT CVD v.2019 primary prevention equation for men (30–74 years)  PREDICT CVD v.2019 primary prevention equation for women with diabetes (30–74 years)  PREDICT CVD v.2019 primary prevention equation for men with diabetes (30–74 years) |

Each of the equations is denoted by a SNOMED assessment scale concept created for this purpose in the SNOMED NZ Edition. These concepts will be grouped under SNOMED concepts equivalent to the two Enigma codes, and these grouper concepts will themselves be grouped under parent concept [New Zealand cardiovascular disease risk assessment primary prevention equations](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50671000210108&edition=MAIN/SNOMEDCT-NZ/2020-04-01&release=&languages=en).

Any change to each equation, its variables, coefficients or other calculation details, will result in the creation of a new version of the equation, represented by a new SNOMED concept.

#### Performing the calculation

Using the correct equation for the patient, the five-year CVD risk is calculated as a percentage:

(1-Baseline survival function exp (sum of (coefficients \* variables))) \* 100

Each equation has a defined set of input variables and coefficients. Each variable must have a valid value before the equations can be applied. Some variables have a mean for centring. In these cases, subtract the mean from the input value before multiplying by the coefficient. Other variables involve other specified calculations. In these cases, apply the specified calculation and multiply the result by the coefficient.

#### Rounding the score

There is a statistical confidence interval around each estimated risk. Given this imprecision, it is appropriate to round up or down the calculated score to the nearest whole number. For example, if the CVD risk is calculated as 14.641%, the rounded risk score to quote is 15%.

All calculated CVD risk scores must be saved in the patient’s health record, noting the equation used. The rationale for this is so that new CVD risk scores are clearly distinguishable from previous Framingham scores and from each other.

#### Risk scores that are very low or very high

No person is at 0% risk of a CVD event. Therefore, where a patient’s risk is less than 1%, the actual risk displayed should be rounded up to 1%. It is incredibly unlikely for any patient to have a have a CVD risk score over 80%. However, due to the way a CVD risk score is calculated, it is technically possible for a result over 100%. If such a risk score is produced (eg, for people testing a calculator and inputting unlikely clinical parameters) then it should be rounded down to 99%.

#### Risk assessment outside the 30 to 74 years age range

The primary prevention risk prediction equations were developed from a cohort of people aged 30 to 74 years who were eligible for CVD risk prediction according to the 2003 CVD risk assessment and management guidelines and subsequent updates (New Zealand Guidelines Group 2003).

People aged 18-29 years are outside of the age range for which the algorithms were developed and estimating their CVD risk with these equations will only provide a very approximate estimate. Clinical judgement is therefore recommended when using these equations in younger people. However, a risk calculation may be potentially useful to guide clinical decision making for some younger people considered to be at high CVD risk. With this caveat, the guidelines recommend using age 30 years as input to the calculator for those aged 18-29 years.

People aged 75-79 years are also outside of the range for which the algorithms were developed but assessment of the equations performance (calibration) shows that they perform reasonably well. Therefore, inputting the actual age of people aged 75 to 79 years is appropriate.

For people aged 80 years and older, the CVD risk equations do not perform well. Clinical judgement is therefore recommended when using these equations in these older people. However, a risk calculation may be potentially useful to guide clinical decision making. With this caveat, the guidelines recommend using age 80 years as the age input to the calculator when estimating risk in people aged 80 years and older.

|  |  |  |
| --- | --- | --- |
| **Age** | **Input to calculator** | **Note** |
| 18-29 years | Input age 30 years | Outside age range for which the algorithms were developed; CVD risk is an approximation only |
| 30-74 years | Input actual age | Age group used to derive equations |
| 75 -79 years | Input actual age | Outside age range for which the algorithms were developed but current equations perform reasonably well |
| 80+ years | Input age 80 years | Outside age range for which the algorithms were developed; CVD risk is an approximation only |

#### Recording the assessed risk score

[New Zealand cardiovascular disease 5-year risk score](https://browser.ihtsdotools.org/?perspective=full&conceptId1=50571000210107&edition=MAIN/SNOMEDCT-NZ/2020-04-01) is the SNOMED CT observable entity concept used to denote the assessed risk score in the patient record. Each risk score should be recorded with both this observable entity concept and the SNOMED CT identifier for the assessment scale concept representing the correct version of the correct equation.

## PREDICT CVD v.2019 primary prevention equation for women (30–74 years)

|  |  |  |
| --- | --- | --- |
| **Variable** | **Coefficient** | **Mean for centring** |
| Age (centred) | 0.0734393 | 56.05801 |
| Māori | 0.4164622 |  |
| Pacific | 0.2268597 |  |
| Indian/Other South Asian | 0.2086713 |  |
| Chinese/Asian | -0.2680559 |  |
| NZDep quintile (centred) | 0.0957229 | 2.994877 |
| Ex-smoking | 0.1444243 |  |
| Currently smoking | 0.6768396 |  |
| Family history of premature CVD | 0.0645588 |  |
| Atrial fibrillation | 0.9293084 |  |
| Diabetes | 0.4967444 |  |
| Systolic BP (centred) | 0.0176523 | 128.6736 |
| TC:HDL-C (centred) | 0.1361335 | 3.715383 |
| BMI: |  |  |
| 1. Normal (18.5–24.9) |  |  |
| 1. Underweight (<18.5) | 0.6277962 |  |
| 1. Overweight (25.0–29.9) | 0.0018215 |  |
| 1. Obesity class 1 (30.0–34.9) | -0.0169324 |  |
| 1. Obesity class 2 (35.0–39.9) | 0.0343351 |  |
| 1. Obesity class 3 (40.0+) | 0.3196519 |  |
| 1. BMI unknown | 0.0213595 |  |
| On BP-lowering medication | 0.3487781 |  |
| On lipid-lowering medication | -0.0568366 |  |
| On either antiplatelet or anticoagulant medications | 0.1393368 |  |
| Age (centred) x diabetes | -0.0189779 |  |
| Age (centred) x systolic BP (centred) | -0.000471 |  |
| On BP-lowering medication x systolic BP (centred) | -0.0054002 |  |
| Baseline survival function (women) at five years | 0.9845026 |  |

## PREDICT CVD v.2019 primary prevention equation for men (30–74 years)

|  |  |  |
| --- | --- | --- |
| **Variable** | **Coefficient** | **Mean for centring** |
| Age (centred) | 0.0669484 | 51.59444 |
| Māori | 0.3166164 |  |
| Pacific | 0.2217931 |  |
| Indian/Other South Asian | 0.3666816 |  |
| Chinese/Asian | -0.4131973 |  |
| NZDep quintile (centred) | 0.0631146 | 2.975732 |
| Ex-smoking | 0.0748648 |  |
| Currently smoking | 0.5317607 |  |
| Family history of premature CVD | 0.1275721 |  |
| Atrial fibrillation | 0.6250334 |  |
| Diabetes | 0.4107586 |  |
| Systolic BP(centred) | 0.0179827 | 128.8637 |
| TC:HDL-C (centred) | 0.1296756 | 4.385853 |
| BMI: |  |  |
| 1. Normal (18.5–24.9) |  |  |
| 1. Underweight (< 18.5) | 0.5488212 |  |
| 1. Overweight (25.0–29.9) | -0.033177 |  |
| 1. Obesity class 1 (30.0–34.9) | -0.0025986 |  |
| 1. Obesity class 2 (35.0–39.9) | 0.1202739 |  |
| 1. Obesity class 3 (40.0+) | 0.3799261 |  |
| 1. BMI unknown | -0.073928 |  |
| On BP-lowering medication | 0.2847596 |  |
| On lipid-lowering medication | -0.0256429 |  |
| On either antiplatelet or anticoagulant medications | 0.0701999 |  |
| Age (centred) x diabetes | -0.0124356 |  |
| Age (centred) x systolic BP (centred) | -0.0004931 |  |
| On BP-lowering medication x systolic BP (centred) | -0.0049226 |  |
| Baseline survival function (men) at five years | 0.9712501 |  |

## PREDICT CVD v.2019 primary prevention equation for women with diabetes (30–74 years)

|  |  |  |
| --- | --- | --- |
| **Variable** | **Coefficient** | **Mean for centring** |
| Age (centred) | 0.0424465 | 53.598009 |
| Māori | 0.0770441 |  |
| Pacific | -0.2533 |  |
| Indian/Other South Asian | 0.138371 |  |
| Chinese/Asian | -0.3611259 |  |
| NZDep quintile (centred) | 0.0699105 | 3.657006 |
| Currently smoking | 0.4391752 |  |
| Family history of premature CVD | 0.1063846 |  |
| Atrial fibrillation | 0.7864886 |  |
| Systolic BP(centred) | 0.0127053 | 131.380365 |
| TC:HDL-C (centred) | 0.1139678 | 3.970698 |
| BMI (centred) | 0.0073966 | 33.515572 |
| Years since diagnosis of type 2 diabetes (centred) | 0.0163962 | 5.406364 |
| eGFR (centred) | -0.0090784 | 89.558866 |
| ACR (centred, log transformed and scaled) | 0.1842885 | Calculation producing centred value:  loge(X) + 4.314302355 where X = (ACR + 0.0099999997764826)/1000 |
| HbA1c (centred) | 0.0076733 | 63.618622 |
| On oral hypoglycaemic medication | 0.1248604 |  |
| On insulin | 0.3535548 |  |
| On BP-lowering medication | 0.0988141 |  |
| On lipid-lowering medication | -0.1595083 |  |
| On either antiplatelet or anticoagulant medications | 0.0605766 |  |
| Baseline survival function (women) at five years | 0.945571 |  |

## PREDICT CVD v.2019 primary prevention equation for men with diabetes (30–74 years)

|  |  |  |
| --- | --- | --- |
| **Variable** | **Coefficient** | **Mean for centring** |
| Age (centred) | 0.0472422 | 53.738152 |
| Māori | -0.0553093 |  |
| Pacific | -0.210811 |  |
| Indian/Other South Asian | 0.1522338 |  |
| Chinese/Asian | -0.3852922 |  |
| NZDep quintile (centred) | 0.0413719 | 3.410281 |
| Currently smoking | 0.3509447 |  |
| Family history of premature CVD | 0.2093793 |  |
| Atrial fibrillation | 0.5284553 |  |
| Systolic BP (centred) | 0.0054797 | 131.662168 |
| TC:HDL-C (centred) | 0.0805627 | 4.330372 |
| BMI (centred) | 0.0117137 | 31.338254 |
| Years since diagnosis of type 2 diabetes (centred) | 0.0162351 | 5.183025 |
| eGFR (centred) | -0.0025889 | 88.788314 |
| ACR (centred, log transformed and scaled) | 0.1815067 | Calculation producing centred value:  loge(X) + 4.275179 where X = (ACR + 0.0099999997764826)/1000 |
| HbA1c (centred) | 0.0074805 | 63.889441 |
| On oral hypoglycaemic medication | 0.0051476 |  |
| On insulin | 0.1846547 |  |
| On BP-lowering medication | 0.1532122 |  |
| On lipid-lowering medication | -0.0344494 |  |
| On either antiplatelet or anticoagulant medications | 0.0474684 |  |
| Baseline survival function (men) at five years | 0.9121175 |  |

# Test cases and worked examples

Test cases and worked examples have been developed to assist software suppliers to check the behaviour of their calculators. See the associated spreadsheet for the test cases. The set of test cases, although not exhaustive, represents a reasonable clinical range of patient profiles.

The following four worked examples show how a risk score is calculated using each of the equations. Refer to the above tables and rules. To aid accuracy we have presented the calculated score to three decimal points.

## Patient A

**PREDICT CVD v.2019 primary prevention equation for women (for the general population)**

Patient A is an Indian woman aged 55 years, with diabetes and a BMI of 41 kg/m2. She is a former smoker, lives in an area categorised as NZDep quintile 5, has a family history of premature CVD and has atrial fibrillation. Her systolic blood pressure is 120mmHg and her TC:HDL is 3.2 units. She is taking blood pressure-lowering medication, a statin and an antithrombotic medication.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Value** | **Coefficient x variable** | **Product** |
| Age, years | 55 years | 0.0734393 x (55 – 56.05801) | -0.0776995 |
| Māori |  | 0.4164622 x 0 | 0 |
| Pacific |  | 0.2268597 x 0 | 0 |
| Indian/Other South Asian | Yes | 0.2086713 x 1 | 0.2086713 |
| Chinese/Asian |  | -0.2680559 x 0 | 0 |
| NZDep quintile | 5 | 0.0957229 x (5 - 2.994877) | 0.1919362 |
| Ex-smoking | Yes | 0.1444243 x 1 | 0.1444243 |
| Currently smoking |  | 0.6768396 x 0 | 0 |
| Fam. hist. CVD | Yes | 0.0645588 x 1 | 0.0645588 |
| Atrial fibrillation | Yes | 0.9293084 x 1 | 0.9293084 |
| Diabetes | Yes | 0.4967444 x 1 | 0.4967444 |
| SBP, mmHg | 120 | 0.0176523 x (120 - 128.6736) | -0.1531090 |
| TC:HDL | 3.2 | 0.1361335 x (3.2 - 3.715383) | -0.0701609 |
| BMI < 18.5 kg/m2 |  | 0.6277962 x 0 | 0 |
| BMI 25.0–29.9 kg/m2 |  | 0.0018215 x 0 | 0 |
| BMI 30.0–34.9 kg/m2 |  | -0.0169324 x 0 | 0 |
| BMI 35.0–39.9 kg/m2 |  | 0.0343351 x 0 | 0 |
| BMI 40.0+ kg/m2 | 41 | 0.3196519 x 1 | 0.3196519 |
| BMI unknown |  | 0.0213595 x 0 | 0 |
| BP lowering medn | Yes | 0.3487781 x 1 | 0.3487781 |
| Lipid lowering medn | Yes | -0.0568366 x 1 | -0.0568366 |
| Antiplatelet or anticoagulant | Yes | 0.1393368 x 1 | 0.1393368 |
| Age x diabetes | 55, 1 | -0.0189779 x (55 – 56.05801) x 1 | 0.0200788 |
| Age x SBP | 55, 120 | -0.000471 x (55 – 56.05801) x (120 - 128.6736) | -0.0043223 |
| BP lowering med x SBP | 1, 120 | -0.0054002 x 1 x (120 - 128.6736) | 0.0468392 |
| Baseline survival function at five years | 0.9845026 |  |  |
|  |  | **Sum (coefficient x variable)** | **2.5481999** |

For Patient A, 5-year CVD risk = (1- 0.9845026 exp (2.5481999)) x 100 = 0.181 x 100 = 18%

## Patient B

**PREDICT CVD v.2019 primary prevention equation for men (for the general population)**

Patient B is a European man aged 82 years who lives in an area categorised as NZDep quintile 1. He has never smoked, does not have diabetes or atrial fibrillation, and has no family history of premature CVD. His BMI is 23 kg/m2, SBP is 128 mmHg, and TC:HDL is 4 units. He does not take any blood pressure lowering, lipid lowering, antiplatelet or anticoagulant medication.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Value** | **Coefficient x variable** | **Product** |
| Age, years | 82 years | 0.0669484x (80 – 51.59444) | 1.9017068 |
| Māori |  | 0.3166164 x 0 | 0 |
| Pacific |  | 0.2217931 x 0 | 0 |
| Indian/Other South Asian |  | 0.3666816 x 0 | 0 |
| Chinese/Asian |  | -0.4131973 x 0 | 0 |
| NZDep quintile | Quintile 1 | 0.0631146 x (1 - 2.975732) | -0.1246975 |
| Ex-smoking |  | 0.0748648 x 0 | 0 |
| Currently smoking |  | 0.5317607 x 0 | 0 |
| Fam. hist. CVD | No | 0.1275721 x 0 | 0 |
| Atrial fibrillation | No | 0.6250334 x 0 | 0 |
| Diabetes | No | 0.4107586 x 0 | 0 |
| SBP, mmHg | 128 mmHg | 0.0179827 x (128 - 128.8637) | -0.0155317 |
| TC:HDL | 4 units | 0.1296756 x (4 - 4.385853) | -0.0500357 |
| BMI < 18.5 kg/m2 |  | 0. 5488212 x 0 | 0 |
| BMI 25.0–29.9 kg/m2 |  | -0.033177 x 0 | 0 |
| BMI 30.0–34.9 kg/m2 |  | -0.0025986 x 0 | 0 |
| BMI 35.0–39.9 kg/m2 |  | 0. 1202739 x 0 | 0 |
| BMI 40.0+ kg/m2 |  | 0. 799261 x 0 | 0 |
| BMI unknown |  | -0.073928 x 0 | 0 |
| BP lowering medn | No | 0.2847596 x 0 | 0 |
| Lipid lowering medn | No | -0. 0256429 x 0 | 0 |
| Antiplatelet or anticoagulant | No | 0. 0701999 x 0 | 0 |
| Age x diabetes | 82 years & doesn’t have diabetes | -0. 0124356 x (80 – 51.59444) x 0 | 0 |
| Age x SBP | 82 years & 128 mmHg | -0.0004931 x (80 – 51.59444) x (128 - 128.8637) | 0.0120977 |
| BP lowering med x SBP | Not on BP lowering & 128 mmHg | -0.0049226 x 0 x (128 - 128.8637) | 0 |
| Baseline survival function at five years | 0. 9712501 |  |  |
|  |  | **Sum (coefficient x variable)** | **1.7235395** |

For Patient B, 5-year CVD risk = (1- 0. 9712501 exp (1.7235395)) x 100 = 0.151 x 100 = 15%

## Patient C

**PREDICT CVD v.2019 primary prevention equation for women with diabetes**

Patient D is a Pacific woman aged 75 who lives in an area categorised as NZDep quintile 3. She has had diabetes for 3 years and her latest HbA1c is 56 mmol/mol. She has never smoked, does not have atrial fibrillation, and does not have a family history of premature CVD. Her BMI is 31 kg/m2, SBP is 130 mmHg, TC:HDL is 4, ACR is 1.4 mg/mmol, and eGFR is 92 mL/min/1.73 m2. She takes an oral hypoglycaemic for her diabetes and a statin for lipid lowering but does not take any blood pressure medication, antiplatelet or anticoagulant.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Value** | **Coefficient x variable** | **Product** |
| Age, years | 75 | 0.0424465 x (75 - 53.598009) | 0.9084396 |
| Māori |  |  |  |
| Pacific | Yes | -0.2533x 1 | -0.2533000 |
| Indian/Other South Asian |  |  |  |
| Chinese/Asian |  |  |  |
| NZDep quintile | 3 | 0.0699105 x (3 - 3.657006) | -0.0459316 |
| Currently smoking | No | 0.4391752 x 0 | 0 |
| Fam. hist. CVD | No | 0.1063846 x 0 | 0 |
| Atrial fibrillation | No | 0.7864886 x 0 | 0 |
| SBP, mmHg | 130 | 0.0127053 x (130 - 131.380365) | -0.0175380 |
| TC:HDL | 4 | 0.1139678 x (4 - 3.970698) | 0.0033395 |
| BMI, kg/m2 | 31 | 0.0073966 x (31 - 33.515572) | -0.0186067 |
| Years since diagnosis of type 2 diabetes | 3 | 0.0163962x (3 - 5.406364) | -0.0394552 |
| eGFR, mL/min/1.73 m2 | 92 | -0.0090784 x (92 - 89.558866) | -0.0221616 |
| ACR, mg/mmol | 1.4 | 0. 1842885 x (loge(X)\* - (-4.314302355)) where X =  (ACR + 0.0099999997764826)/1000 | -0.4146239 |
| HbA1c, mmol/mol | 56 | 0.0076733 x (56 - 63.618622) | -0.0584600 |
| Oral hypoglyc. medn | Yes | 0.1248604 x 1 | 0.1248604 |
| Insulin | No |  |  |
| BP lowering medn | No |  |  |
| Lipid lowering medn | Yes | -0.1595083 x 1 | -0.1595083 |
| Antiplatelet or anticoagulant | No |  |  |
| Baseline survival function at five years | 0. 945571 |  |  |
|  |  | **Sum (coefficient x variable)** | **0.0070542** |

For Patient C, 5-year CVD risk = (1 - 0. 945571 exp (0.0070542)) x 100 = 0.0548 x 100 = 5%

## Patient D

**PREDICT CVD v.2019 primary prevention equation for men with diabetes**

Patient C is a NZ Māori man aged 35 who lives in an area categorised as NZDep quintile 5. He has had diabetes for 1 year and his latest HbA1c is 48 mmol/mol. He smokes, has atrial fibrillation, and has a family history of premature CVD. His BMI is 27 kg/m2, SBP is 120 mmHg, TC:HDL is 3.3, ACR is 1 mg/mmol and eGFR is 78 mL/min/1.73 m2. He does not take insulin or an oral hypoglycaemic for his diabetes, and does not take any medication for blood pressure, cholesterol, antiplatelet or anticoagulant.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Value** | **Coefficient x variable** | **Product** |
| Age, years | 35 | 0.0472422 x (35 - 53.738152) | -0.8852315 |
| Māori | Yes | -0.0553093 x 1 | -0.0553093 |
| Pacific |  | -0.210811 x 0 | 0 |
| Indian/Other South Asian |  | 0.1522338 x 0 | 0 |
| Chinese/Asian |  | -0.3852922 x 0 | 0 |
| NZDep quintile | 5 | 0.0413719 x (5 - 3.410281) | 0.0657697 |
| Currently smoking | Yes | 0.3509447 x 1 | 0.3509447 |
| Fam. hist. CVD | Yes | 0.2093793 x 1 | 0.2093793 |
| Atrial fibrillation | Yes | 0.5284553 x 1 | 0.5284553 |
| SBP, mmHg | 120 | 0.0054797 x (120 - 131.662168) | -0.0639052 |
| TC:HDL | 3.3 | 0.0805627 x (3.3 - 4.330372) | -0.0830096 |
| BMI, kg/m2 | 27 | 0.0117137 x (27 - 31.338254) | -0.0508170 |
| Years since diagnosis of type 2 diabetes | 1 | 0.0162351 x (1 - 5.183025) | -0.0679118 |
| eGFR, mL/min/1.73 m2 | 78 | -0.0025889 x (78 - 88.788314) | 0.0279299 |
| ACR, mg/mmol | 1 | 0.1815067 x (loge(X)\* - (-4.275179)) where X =  (ACR + 0.0099999997764826)/1000 | -0.4760242 |
| HbA1c, mmol/mol | 48 | 0.0074805 x (48 - 63.889441) | -0.1188610 |
| Oral hypoglyc. medn | No | 0.0051476 x 0 | 0 |
| Insulin | No | 0.1846547 x 0 | 0 |
| BP lowering medn | No | 0.1532122 x 0 | 0 |
| Lipid lowering medn | No | -0.0344494 x 0 | 0 |
| Antiplatelet or anticoagulant | No | 0.0474684 x 0 | 0 |
| Baseline survival function at five years | 0. 9121175 |  |  |
|  |  | **Sum (coefficient x variable)** | **-0.6185907** |

For Patient D, 5-year CVD risk = (1 - 0. 9121175 exp (-0.6185907)) x 100 = 0.048 x 100 = 5%

# Requirements for software tools

Patient communication and joint clinical and patient decision-making are critical components of the CVD risk assessment and management process. A primary care practitioner needs to be able to communicate risk effectively to the patient and should also recognise that decision support tools for different levels of health literacy are useful adjuncts to help patients understand risk.

Software tools implementing the equations and supporting communication and health literacy should be able to:

* calculate and present the individual’s estimated five-year CVD risk, heart age and risk trajectory
* show the effect of a range of interventions, including:
* lifestyle changes such as smoking cessation, increasing physical activity, dietary change and reducing alcohol
* medications such as statins, antihypertensive medicines and aspirin
* present estimated five-year CVD risk with and without intervention as a graphic (for example, as side-by-side displays of absolute risk, each showing 100 faces or figures and the percentage at risk)
* account for the specific exclusion criteria and do not allow CVD risk calculation if any are present.

These software tools should also be very usable, interoperable and secure:

* Tools interoperate with patient management systems and patient portals.
* Tools automatically populate from the patient’s health record and save risk results back into the record.
* The patient can use these tools to access their risk assessment online.
* The clinician can print a copy of a patient’s risk assessment and management advice.
* Tools are easily adaptable to new and modified risk equations.
* Tools are secure and protect patient privacy.

# References

1. Wells S, Riddell T, Kerr A, et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). International Journal of Epidemiology 2015;**doi: 10.1093/ije/dyv312**.

2. Ministry of Health. Cardiovascular disease risk assessment and management for primary care. Wellington: Ministry of Health, 2018.

3. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;**391**(10133):1897-907.

4. New Zealand Guideline Group. *The Assessment and Management of Cardiovascular Risk*. Wellington, New Zealand, 2003.

5. Ministry of Health. HISO 10001:2017 Ethnicity Data Protocols. Wellington: Ministry of Health, 2017.

6. Salmond C, Crampton P, Atkinson J. NZDep2006 Index of Deprivation User's Manual. Wellington: ; 2007. Wellington: Department of Public Health, Wellington School of Medicine and Health Sciences, 2007.

7. Salmond C, Crampton P, King P, et al. NZiDep: A New Zealand index of socioeconomic deprivation for individuals. Social Science & Medicine 2006;**62**(6):1474-85.

1. See https://standards.iso.org/ittf/PubliclyAvailableStandards/index.html [↑](#footnote-ref-2)